Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus

European Cytokine Network

Volumn 18, Issue 4, 2007, Pages 181-187

  Robak, Ewa ^a   Kulczycka, Lilianna ^a   Sysa Jȩdrzejowska, Anna ^a   Wierzbowska, Agnieszka ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Disease activity; PIGF; SDF 1; SLE; sVCAM 1; VEGF

Indexed keywords

ANGIOGENIC FACTOR; AZATHIOPRINE; CYTOKINE; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; PLACENTAL GROWTH FACTOR; PREDNISONE; STEROID; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CHEMOKINE CXCL12; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37849011234     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2007.0103     Document Type: Article

References (36)

1. D'Cruz D. Vasculitis in systemic lupus erythematosus. Lupus 1998; 7: 270.
2. Ferrara N. VEGF: basic science and clinical progress. Endocr Rev 2004; 25: 581.
3. Failla CM, Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci 2006; 41: 11.
4. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242.
5. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002; 64: 162.
6. Middleton J, Patterson AM, Gardnern L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002; 100: 3853.
7. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217.
8. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapte HIV-1. Nature 1996; 382: 833.
9. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004; 109: 2487.
10. Lewis MJ, D'Cruz D. Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus. Lupus 2005; 14: 17.
11. Devaraj S, O'Keefe G, Jialal I. Defining the pro-inflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005; 8: 4549.
12. Mitsias DI, Kapsogeorgou EK, Moutsopolous HM. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjögren's syndrome (autoimmune epithelitis). Lupus 2006; 15: 255.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271.
14. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107.
15. Robak T, Wierzbowska A, Blasinska-Morawiec M, Korycka A, Blonski JZ. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediat Inflamm 1999; 8: 277.
16. Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149.
17. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357.
18. Robak E, Woźzniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw 2001; 12: 445.
19. Robak E, Sysa-Jȩdrzejowska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediat Inflammation 2003; 12: 293.
20. Robak E, Woźniacka A, Sysa-Jȩdrzejowska A, Stȩpień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348.
21. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575.
22. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation or vascular growth factor bioactivity, in vitro and in vivo and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646.
23. Claus M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implication for a functional role of placenta growth factor in monocyte activation and Chemotaxis. J Biol Chem 1996; 271: 17629.
24. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1 selective VEGF homologue PIGF is arteriogenic. Evidence for a monocyte-mediated mechanism. Circ Res 2003; 92: 378.
25. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR-1 + stem cells from bone marrow microenvironment. Nat Med 2002; 8: 841.
26. Cianfarani F, Zambruno G, Brogelli L, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 2006; 69: 1167.
27. Botomley MJ, Webb NJ, Watson CJ, et al. Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 2000; 119: 182.
28. Sbaa E, Dewever J, Martinive P, et al. Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven post ischemic vasculogenesis. Circ Res 2006; 98: 1219.
29. Balabanian K, Couderc J, Bouchet-Delbos L, et al. Role of the chemokine stromal cell derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003; 170: 3392.
30. Sela U, Hershkoviz R, Cahalon L, Lider O, Mozes E. Downregulation of stromal cell derived factor-1α induced T cell Chemotaxis by a peptide based on the complementarity determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-β secretion. J Immunol 2005; 174: 302.
31. De Klerck B, Geboes L, Hatse S, et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 2005; 7: R1208.
32. Ho CY, Wong CK, Li EK, Tan LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatol 2003; 42: 117.
33. Janssen BA, Laqmani RA, Gordon C, et al. Correlation or blood levels of soluble vascular adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33: 1112.
34. Ikeda Y, Fujimoto T, Ameno M, Shiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998; 7: 347.
35. Kaplanski G, Cacoub P, Maisonobe T, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus related antiphospholipid syndrome. Arthritis Rheum 2000; 43: 55.
36. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97: 439.